These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 4146086)

  • 1. Pharmacokinetics and azo-link cleavage of salazopyrine in man.
    Lewkonia RM; Schröder H; Evans DA
    Gut; 1973 May; 14(5):426-7. PubMed ID: 4146086
    [No Abstract]   [Full Text] [Related]  

  • 2. The role of the colon in the metabolism of salicylazosulphapyridine.
    Das KM; Eastwood MA; McManus JP; Sircus W
    Scand J Gastroenterol; 1974; 9(2):137-41. PubMed ID: 4150441
    [No Abstract]   [Full Text] [Related]  

  • 3. A possible mechanism of action of sulfasalazine and 5-aminosalicylic acid in inflammatory bowel diseases: interaction with oxygen free radicals.
    Del Soldato P; Campieri M; Brignola C; Bazzocchi G; Gionchetti P; Lanfranchi GA; Tamba M
    Gastroenterology; 1985 Nov; 89(5):1215-6. PubMed ID: 2864302
    [No Abstract]   [Full Text] [Related]  

  • 4. Distribution studies of salicylazosulfapyridine and its metabolites.
    Peppercorn MA; Goldman P
    Gastroenterology; 1973 Feb; 64(2):240-5. PubMed ID: 4405598
    [No Abstract]   [Full Text] [Related]  

  • 5. Influence of intestinal transit time on azo-reduction of salicylazosulphapyridine (Salazopyrin).
    van Hees PA; Tuinte JH; van Rossum JM; van Tongeren JH
    Gut; 1979 Apr; 20(4):300-4. PubMed ID: 36332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Letter: Salicylazosulfapyridine in clinical practice.
    Daz KM
    Gastroenterology; 1974 Feb; 66(2):326. PubMed ID: 4149356
    [No Abstract]   [Full Text] [Related]  

  • 7. Absorption, metabolism, and excretion of salicylazosulfapyridine in man.
    Schröder H; Campbell DE
    Clin Pharmacol Ther; 1972; 13(4):539-51. PubMed ID: 4402886
    [No Abstract]   [Full Text] [Related]  

  • 8. [Salazosulfapyridine or 5-aminosalicylic acid].
    Terpstra JJ
    Ned Tijdschr Geneeskd; 1987 Aug; 131(32):1409-10. PubMed ID: 2889151
    [No Abstract]   [Full Text] [Related]  

  • 9. Colonic azodisalicylate metabolism determined by in vivo dialysis in healthy volunteers and patients with ulcerative colitis.
    Lauritsen K; Hansen J; Ryde M; Rask-Madsen J
    Gastroenterology; 1984 Jun; 86(6):1496-500. PubMed ID: 6143704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Current concepts on the pharmacokinetics of salazopyrine and new therapeutic trends in ulcerohemorrhagic rectocolitis].
    Gheorghescu B
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna; 1981; 33(5):339-44. PubMed ID: 6122244
    [No Abstract]   [Full Text] [Related]  

  • 11. Capacity-limited gut wall metabolism of 5-aminosalicylic acid, a therapeutically active metabolite of sulfasalazine, in rats.
    Pieniaszek HJ; Bates TR
    J Pharm Sci; 1979 Oct; 68(10):1323-5. PubMed ID: 41931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 5-aminosalicylic acid in a slow-release preparation: bioavailability, plasma level, and excretion in humans.
    Rasmussen SN; Bondesen S; Hvidberg EF; Hansen SH; Binder V; Halskov S; Flachs H
    Gastroenterology; 1982 Nov; 83(5):1062-70. PubMed ID: 7117789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Salazopyrin metabolism in ulcerative colitis.
    Das KM; Eastwood MA; Macmanus JP; Sircus W
    Gut; 1972 Oct; 13(10):840. PubMed ID: 4404480
    [No Abstract]   [Full Text] [Related]  

  • 14. Determination of sodium azodisalicylate, salazosulphapyridine and their metabolites in serum, urine and faeces by high-performance liquid chromatography.
    van Hogezand RA; van Balen HC; van Schaik A; Tangerman A; van Hees PA; Zwanenburg B; van Tongeren JH
    J Chromatogr; 1984 Feb; 305(2):470-6. PubMed ID: 6142900
    [No Abstract]   [Full Text] [Related]  

  • 15. Determination of free and acetylated 5-aminosalicylic acid in serum and urine after administration of salicylazosulphapyridine.
    Hansson KA
    Acta Pharm Suec; 1973 May; 10(2):153-5. PubMed ID: 4146997
    [No Abstract]   [Full Text] [Related]  

  • 16. [Current orientation in medical management of ulcerative colitis].
    Grassi M; Raffa S; Damiani VC; Fontana M
    Clin Ter; 1995 May; 146(5):327-41. PubMed ID: 7796565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New derivates of salazopyrine in the treatment of chronic inflammatory bowel disease].
    Broide E; Scapa E; Abramowich D; Eshchar Y
    Harefuah; 1993 Feb; 124(4):223-5. PubMed ID: 8098698
    [No Abstract]   [Full Text] [Related]  

  • 18. The prophylactic effect of 5-aminosalicylic acid and salazosulphapyridine on degraded-carrageenan-induced colitis in guinea pigs.
    Jensen BH; Andersen JO; Poulsen SS; Skov Olsen P; Nørby Rasmussen S; Hansen SH; Hvidberg EF
    Scand J Gastroenterol; 1984 May; 19(3):299-303. PubMed ID: 6146186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse effects of sulfasalazine and treatment of ulcerative colitis with mesalazine.
    Nakajima H; Munakata A; Yoshida Y
    J Gastroenterol; 1995 Nov; 30 Suppl 8():115-7. PubMed ID: 8563870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The short- and long-term safety of 5-aminosalicylate products in the treatment of ulcerative colitis.
    Baker DE; Kane S
    Rev Gastroenterol Disord; 2004; 4(2):86-91. PubMed ID: 15185719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.